A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

被引：0
|
作者：
Weiss, G. [1 ]
Donehower, R. [2 ]
Westin, E. [3 ]
Bence, A. [4 ]
Hynes, S. [5 ]
Hurt, K. [6 ]
机构：
[1] TGEN Clin Res, Canc & Cell Biol Div, Scottsdale, AZ USA
[2] Johns Hopkins Univ, Med Ctr, Baltimore, MD 21218 USA
[3] Eli Lilly & Co, Med Oncol Exploratory Preclin, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Program Phase, Indianapolis, IN 46285 USA
[6] Eli Lilly & Co, Clin Oncol, Indianapolis, IN 46285 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72223-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [1] Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer
    Weiss, Glen J.
    Donehower, Ross C.
    Iyengar, Tara
    Ramanathan, Ramesh K.
    Lewandowski, Karen
    Westin, Eric
    Hurt, Karla
    Hynes, Scott M.
    Anthony, Stephen P.
    McKane, Scott
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 136 - 144
  • [2] Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer
    Glen J. Weiss
    Ross C. Donehower
    Tara Iyengar
    Ramesh K. Ramanathan
    Karen Lewandowski
    Eric Westin
    Karla Hurt
    Scott M. Hynes
    Stephen P. Anthony
    Scott McKane
    Investigational New Drugs, 2013, 31 : 136 - 144
  • [3] A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642).
    Shih, K. C.
    Infante, J. R.
    Papadopoulos, K. P.
    Bendell, J. C.
    Tolcher, A. W.
    Burris, H. A.
    Beeram, M.
    Jackson, L.
    Arcos, R.
    Westin, E. H.
    Farrington, D.
    McGlothlin, A.
    Hynes, S.
    Leohr, J.
    Brandt, J. T.
    Nasir, A.
    Patnaik, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer
    Wehler, Thomas
    Thomas, Micheal
    Schumann, Chirstian
    Bosch-Barrera, Joaquim
    Segarra, Nuria Vinolas
    Dickgreber, Nicolas J.
    Dalhoff, Klaus
    Sebastian, Martin
    Jaime, Jesus Corral
    Alonso, Miriam
    Hynes, Scott M.
    Lin, Ji
    Hurt, Karla
    Lin, Aimee Bence
    Calvo, Emiliano
    Paz-Ares, Luis
    LUNG CANCER, 2017, 108 : 212 - 216
  • [5] A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
    Greil, Richard
    Greil-Ressler, Sigrun
    Weiss, Lukas
    Schoenlieb, Charlotte
    Magnes, Teresa
    Radl, Bianca
    Bolger, Gordon T.
    Vcelar, Brigitta
    Sordillo, Peter P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 695 - 706
  • [6] A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
    Richard Greil
    Sigrun Greil-Ressler
    Lukas Weiss
    Charlotte Schönlieb
    Teresa Magnes
    Bianca Radl
    Gordon T. Bolger
    Brigitta Vcelar
    Peter P. Sordillo
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 695 - 706
  • [7] Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors
    E. Calvo
    J. B. Vermorken
    S. Hiret
    J. Rodon
    J. Cortes
    H. Senellart
    J. Van den Brande
    J. Dyck
    A. Pétain
    P. Ferre
    J. Bennouna
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1467 - 1475
  • [8] Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors
    Calvo, E.
    Vermorken, J. B.
    Hiret, S.
    Rodon, J.
    Cortes, J.
    Senellart, H.
    Van den Brande, J.
    Dyck, J.
    Petain, A.
    Ferre, P.
    Bennouna, J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1467 - 1475
  • [9] A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours
    Scheulen, M.
    Mross, K.
    Richly, H.
    Nokay, B.
    Frost, A.
    Scharr, D.
    Lee, K. H.
    Saunders, O.
    Hilbert, J.
    Fietz, O.
    EJC SUPPLEMENTS, 2010, 8 (07): : 158 - 159
  • [10] A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.
    Scheulen, M. E.
    Mross, K. B.
    Richly, H.
    Nokay, B.
    Frost, A.
    Scharr, D.
    Lee, K.
    Saunders, O.
    Hilbert, J.
    Fietz, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345